KRAS and non-small cell lung carcinoma: KRAS oncogenes are the most commonly mutated oncogenes in non-small cell lung cancer, but effective therapeutic strategies to target RAS-mutant cancers have proved elusive since direct inhibition of RAS proteins has proved difficult (18).